Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
申请人:Majid Nadeem Tahir
公开号:US20050009859A1
公开(公告)日:2005-01-13
Compounds of the formula I
are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
公式I的化合物适用于制造用于预防和治疗疾病的药物,这些疾病的病程涉及NIK活性增加。
[EN] PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE PYRAZOLOISOQUINOLINE UTILES COMME INHIBITEURS DE KINASE
申请人:AVENTIS PHARMA INC
公开号:WO2005012301A1
公开(公告)日:2005-02-10
Novel pyrazoloisoquinoline derivatives as kinase inhibitors are disclosed which are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase
申请人:Aventis Pharma Deutschland GmbH
公开号:US20040097541A1
公开(公告)日:2004-05-20
Compounds of the formula I
1
are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
公式I1的化合物适用于生产用于预防和治疗疾病的药物,这些疾病的过程涉及NIK活性的增加。
PYRAZOLOISOQUINOLINENDERIVATEN ZUR INHIBIERUNG VON NFKAPPAB-INDUZIERENDE KINASE
申请人:Sanofi-Aventis Deutschland GmbH
公开号:EP1519934B1
公开(公告)日:2007-09-19
PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS